Early Environmental and Maternal Determinants of Airway Inflammation in Wheezing Disorders in Infants

This study collects data on microbiological, genetic and environmental factors, as well as lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess the complex interaction of predisposing risk factors for impaired lung development and respiratory diseases.

Study Overview

• Status: Enrolling by invitation
• Conditions: Healthy Volunteers
• Intervention / Treatment: Other: No intervention

Detailed Description

Background:

Lung development and growth is a complexly orchestrated process starting prenatally in the first embryonic weeks, and ending, with the last important stages of alveolarization from the 24th week onwards. By the time of birth, around one third of the total amount of alveoli has developed, while the rest develops during infancy and childhood. After birth, lung volume, airways and the gas-exchanging surface increase by a multiple, reaching the maximum lung size at around 25 years of age. A comprehensive understanding of lung growth and development is crucial in order to understand the pathophysiology of lung diseases. During childhood and ongoing lung growth, an important amount of respiratory diseases might develop.

Objectives:

Longitudinal assessment of lung growth and development, to examine respiratory morbidity such as Asthma and allergy, and the complex relationship between associated Risk factors mainly genetic predisposition and environmental factors on both lung development and subsequent respiratory morbidity, Therefore, longitudinal data on lung function and structure, on respiratory morbidity and on genetic, immunological, microbiological and environmental risk factors will be collected.

Methods:

Recruitment and participation:

Participants will be recruited antenatal through advertisement placed at gynaecological Hospital in Bern and by obstetricians or midwives. Interested participants can get further information about the study by telephone from study nurses, as well as during the baseline visit at the University Children's Hospital in Bern, respectively. Mothers with a high risk of a preterm delivery will be informed by clinical Investigators at the Department of Obstetrics of the University Hospital Bern. Preterm infants, which receive ventilatory support over a long period are at Risk for chronical lung diseases in early childhood, named bronchopulmonary dysplasia (BPD). The recruitment of this infants will take place at the neonatology intensive care unit by clinical Investigators. On average 40 healthy children, 40 preterm children and 20 infants from risk pregnancies will be recruited as participants of the BILD cohort each year for Study Phase I. At 3, 6, 9, 12, 15 years and once after the 16th year of age the parents/participants will be asked again, if they would like to participate at the follow-up visits at the University Children's Hospital in Bern for the subsequent Study Phases II and III.

Information collected:

Lung function data:

• Tidal breathing parameters (minute ventilation, respiratory rate, tidal volume, tidal expiratory flow, tidal inspiratory flow, time to peak expiratory flow) averaged over 100 breaths.
• Multiple breath washout (FRC, LCI, moment ratios) and single breath washout (molar mass)
• Fractional exhaled nitric oxide (marker of airway inflammation)
• Spirometric forced expiratory volume loops (FVC, FEV1, PEF, MEF50)
• Body plethysmography (airway resistance, lung volumes: TLC, FRC, RV)
• Respiratory Rate over 60 seconds
• Interrupter resistance measurement (RINT)
• Volatile organic compounds
• Forced oscillation technique (FOT)
• Electrical impedance tomography (EIT)
• Impedance plethysmography (IP)

Microbiological data:

• Nasal swabs (respiratory virus and bacterial diagnostics, as well as host transcriptome Analysis)
• Pharyngeal swabs (bacterial colonization and microbiota Analysis)
• Anterior nasal and oropharyngeal swabs (viral, bacterial and host transcriptome Analysis)
• Nasal brush
• Sputum (to analyse the neutrophils)

Cord blood (mononuclear cells (CBMC) (e.g. lymphocytes)which regulate the innate and adaptive immunity)

Blood count (hemoglobin concentration, hematocrit, leukocyte number, lymphocyte number, lymphocyte count, eosinophil count, basophil count, monocyte count, promyelocyte count, myelocyte count, platelet count, immunoglobulin E Level, Interleukins, Granulocyte-Monocyte-Colony Forming Unit, Tumor Necrosis Factor alpha, Interferon gamma and Interferon lambda)

Urin (to estimate the tobacco exposure during pregnancy (amount of Cotinine) and the content of caffeine and Steroid profile)

Lung function MRI: functional and structural images of the lung

Environmental pollution (Level of particulate matter <10um, Nitrogen dioxide, ozone and particulate matter <2.5um)

Skin-Prick Test (test for pollen, trees, house dust mite, cat and dog)

Questionnaires (to assess quality of life)

Medical history (information on respiratory Symptoms, pulmonary exacerbations, hospitalisations and regular therapy)

Study database:

All study data is recorded in an Access-database with SQL Servers by electronic Case Report Forms. The database is accordant to the HFG and was adapted together with the CTU.

Funding:

Schweizerischer Nationalfonds (SNF) and Departement Lehre und Forschung of the Inselspital Bern.

• Study Type: Observational
• Enrollment (Anticipated): 1000

Contacts and Locations

Study Locations

• Switzerland
  • Bern, Switzerland, 3010
    • University Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Healty term born, healthy preterm born infants and children and white preterm born infants and children from risk pregnancies.

Description

Inclusion Criteria:

• Term Born group (H): Healthy, white and term Born infants and Children. Born 38-42 weeks postconceptional.
• Preterm group (P): Healthy, white preterm Born infants and Children. Born <37 weeks postconceptional. Which comply with the international criteria (Jobe and Bancalari) of a diagnosis of bronchopulmonary dysplasia (BPD), or of chronic lung disease of the new-born (CLD).
• Risk pregnancy group (RP): White preterm Born infants and Children, including Twins. Born <37 weeks postconceptional. With fetal growth restriction (FGR), intrauterine growth restriction (IUGR) or preeclampsia (PE). With gestational Diabetes (GMD). With IVF or Amnion dysfunction.
• Parents: language skills in German or French (by at least one parent).
• Both of the parents can be Smokers and may be atopics (allergy of the mother and/or the Father).
• Signed, written informed consent of the parents.

Exclusion Criteria:

• Term Born group (H): Need of respiratory support > three days postnatal. Severe malformations or known diseases. Maternal drug abuse except smoking. Known sever maternal disease postpartum. Insufficient Knowledge of Project language (no German or French speaker). Pacemaker, continuous glucose monitor.
• Preterm group (P): Severe malformations or known diseases. Maternal drug abuse except smoking. Known severe maternal disease postpartum. Insufficient Knowledge of Project language (no German or French speaker). Pacemaker, continuous glucose monitor.
• Risk pregnancy group (RP): Insufficient Knowledge of Project language (no German or French speaker). Concurrent participation in another study. Participants, which lead to heterogeneity in genetic analysis and thus preclude any findings.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Term born group (H); Healthy, white and term Born infants and Children Born 38-42 weeks postconceptional	Other: No intervention; No intervention
Preterm group (P); Healthy, white preterm Born infants and Children Born <37 weeks postconceptional Which comply with the international criteria (Jobe and Bancalari) of a diagnosis of bronchopulmonary dysplasia (BPD), or of chronic lung disease of the new-born (CLD)	Other: No intervention; No intervention
Risk pregnancy group (RP); White preterm Born infants and Children, including Twins Born <37 weeks postconceptional With fetal growth restriction (FGR), intrauterine growth restriction (IUGR) or preeclampsia (PE) With gestational Diabetes (GDM) With IVF or Amnion dysfunction	Other: No intervention; No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Multiple Breath Washout	Longitudinal assessment of lung volume and ventilation inhomogeneity	Every third year from the age of 4-6 weeks/1 year till >16 years.
Change in Spirometry	Longitudinal assessment of long volumes	Every third year from the age of 4-6 weeks/1 year till >16 years
Change in Body plethysmography	Longitudinal assessment of ventilation inhomogeneity.	Every third year from the age of 4-6 weeks/1 year till >16 years.
Change in Magnetic Resonance Imaging (MRI)	Longitudinal assessment of regional lung perfusion and ventilation	At the age of 4-6 weeks, 1, 3, 6, 9, 12, 15 and >16 years.
Change in Nasal swabs	Longitudinal assessment of viral and bacterial colonization of the nasal swab	At the age of 4-6 weeks, 1, 3, 6, 9, 12, 15 and >16 years.
Change in Weekly swabs	Respiratory virus and bacterial diagnostic	Weekly from the visit at the age of 8-12 weeks till the age of 1 year.
Swabs during respiratory infection	Respiratory viruses and Bacteria, changes of the microbial flora	Any timepoint between the visit at the age of 4-6 weeks till the age of 1 year.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Respiratory Rate (RR)	The number of breaths over 60 seconds	From the visit at the age of 4-6 weeks till the age of 1 year.
Urine	Estimation of tobacco exposure during pregnancy.	At the age of 4-6 weeks.
Cord blood	Assessment of mononuclear cells, which regulate the innate and adaptive immunity.	At birth.
Capillary blood markers	Assessment of blood markers.	At the age of 1, 3, 6, 9, 12, 15 and >16 years.
Skin Prick Test	Assessment of the history of atopy and allergy	At the age of 3, 6, 9, 12, 15 and >16 years.
Environmental pollution markers	Level of particulate matter <10um, Nitrogen dioxide, ozone and particulate matter <2.5um.	At the age of 4-6 weeks, 1, 3, 6, 9, 12, 15 and >16 years.
Volatile organic compound markers	Real-time Analysis of gases.	At the age of 4-6 weeks, 1, 3, 6, 9, 12, 15 and >16 years.
Oropharyngeal swabs	Longitudinal assessment of viral and bacterial colonization.	At the age of 1, 3, 6, 9, 12, 15 and >16 years.
Nasal brushes	Longitudinal assessment of viral and bacterial colonization.	At the age of 1, 3, 6, 9, 12, 15 and >16 years.
Sputum	Longitudinal assessment of the sputum neutrophils.	At the age of (3), 6, 9, 12, 15 and >16 years.

Collaborators and Investigators

• Sponsor: University Hospital Inselspital, Berne
• Investigators: Principal Investigator: Philipp Latzin, MD PhD, University Children's hospital Bern

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2003
• Primary Completion (Anticipated): September 1, 2050
• Study Completion (Anticipated): January 1, 2051

Study Registration Dates

• First Submitted: October 9, 2019
• First Submitted That Met QC Criteria: February 24, 2020
• First Posted (Actual): February 27, 2020

Study Record Updates

• Last Update Posted (Actual): September 29, 2021
• Last Update Submitted That Met QC Criteria: September 28, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: children; infants; healthy; fetal growth restriction; term born; preterm born; intrauterine growth restriction or preeclampsia; with gestational diabetes; with IVF or amnion dysfunction
• Additional Relevant MeSH Terms: Pathologic Processes; Signs and Symptoms, Respiratory; Inflammation; Respiratory Sounds
• Other Study ID Numbers: BILD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No